Table 3 Injection site and injection site reaction after galcanezumab
From: Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
(A) Injection site | ||||||
Dose | Abdomen | Forearm | n | |||
First | 52 (100) | 51 (98.1) | 52 | |||
Second | 14 (27.5) | 37 (72.5) | 51 | |||
Third | 14 (28.0) | 36 (72.0) | 50 | |||
(B) Degree of injection site reaction | ||||||
Dose | None | Mild | Moderate | Severe | n | |
First | 38 (73.1) | 11 (21.2) | 3 (5.8) | 0 (0.0) | 52 | |
Second | 43 (82.7) | 8 (15.4) | 1 (1.9) | 0 (0.0) | 52 | |
Third | 40 (80.0) | 9 (18.0) | 0 (0.0) | 1 (2.0) | 50 | |
(C) Types of injection site reaction | ||||||
Dose | Pain | Redness | Swelling | Numbness | Others | n |
First | 11 (21.2) | 2 (3.8) | 3 (5.8) | 0 (0.0) | 5 (9.6) | 52 |
Second | 7 (13.5) | 4 (7.7) | 4 (7.7) | 0 (0.0) | 1 (1.9) | 52 |
Third | 8 (16.0) | 5 (10.0) | 2 (4.0) | 0 (0.0) | 1 (2.0) | 50 |